FAQ on GeoVax's Call for Pandemic Preparedness and Biodefense Investment

What is GeoVax’s main concern regarding pandemic preparedness?

GeoVax is concerned about the U.S.’s reliance on foreign vaccine suppliers and outdated platforms, urging immediate investment in domestic manufacturing and vaccine diversification to enhance pandemic readiness.

Why is domestic manufacturing of vaccines important according to GeoVax?

Domestic manufacturing is crucial to end foreign vaccine dependency, modernize the nation’s countermeasure infrastructure, and ensure a secure and scalable supply of vaccines for emerging and endemic threats.

What vaccine candidates is GeoVax developing?

GeoVax is developing GEO-MVA for Mpox/smallpox and GEO-CM04S1, a next-generation COVID-19 vaccine, both supported by clinical data and aimed at providing robust immune protection.

How does the current Mpox situation highlight the need for action?

The global spread of Mpox, including new strains and transmission methods, along with the U.S.’s reliance on a single foreign supplier for vaccines, underscores the urgent need for diversified and domestic vaccine production capabilities.

What are the implications of the COVID-19 Nimbus variant?

The Nimbus variant’s dominance and low mRNA vaccine uptake among vulnerable populations highlight the need for broader, longer-lasting immunity options like GeoVax’s GEO-CM04S1 vaccine.

Who is calling for action on pandemic preparedness and biodefense?

GeoVax’s Chairman and CEO David Dodd, along with bipartisan policymakers, are advocating for immediate action to strengthen the U.S.’s biodefense posture and pandemic readiness.

When is the call for action being made?

The call for action is being made now, as of July 30, 2025, in response to escalating outbreak risks and the strain on public health systems.

Where is the need for pandemic preparedness most critical?

The need is critical in the U.S., where the Strategic National Stockpile is overly dependent on foreign vaccine suppliers, but also globally, as diseases like Mpox and COVID-19 variants continue to spread.

What should people know about GeoVax’s vaccine platform?

People should know that GeoVax’s MVA-based vaccine platform is designed to offer multi-antigenic protection against diseases like Mpox and COVID-19, with candidates supported by Phase 2 clinical data and plans for U.S.-based scalable production.

How can the public and policymakers contribute to pandemic preparedness?

The public can support by staying informed and advocating for vaccine diversity, while policymakers can drive change by investing in domestic manufacturing and fostering public-private partnerships for biodefense solutions.